Truist Financial Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $76.00. The company’s shares closed yesterday at $65.47.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Devarakonda is a 4-star analyst with an average return of 9.7% and a 50.60% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Scholar Rock Holding, Coherus Biosciences, and Eli Lilly & Co.

Currently, the analyst consensus on Protagonist Therapeutics is a Strong Buy with an average price target of $73.09, an 11.64% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $80.00 price target.

Based on Protagonist Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $34.77 million. In comparison, last year the company earned a revenue of $4.17 million and had a GAAP net loss of $30.62 million

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTGX in relation to earlier this year. Most recently, in July 2025, DINESH V PH D PATEL, the President & CEO of PTGX sold 10,415.00 shares for a total of $570,533.70.